Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerociclib in advanced breast cancer
NCT05085002Phase 2Terminated
- Sponsor
- EQRx
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of lerociclib in breast cancer, sponsored by EQRx. Started Dec 2021; status: terminated.
02
Drugs
lerociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05085002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085002.